FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048049209> ?p ?o ?g. }

• W3048049209 endingPage "105127" @default.
• W3048049209 startingPage "105127" @default.
• W3048049209 abstract "We formulated a traditional Chinese medicine (TCM) prescription, Hanshiyi Formula (HSYF), which was approved and promoted by the Wuhan Municipal Health Commission for treating mild and moderate coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of HSYF on the progression to severe disease in mild and moderate COVID-19 patients. We conducted a retrospective cohort study of patients with mild and moderate COVID-19 in a quarantine station in Wuchang District, Wuhan. Using the real-time Internet information collection application and Centers for Disease Control for the Wuchang District, patient data were collected through patient self-reports and follow-ups. HSYF intervention was defined as the exposure. The primary outcome was the proportion of patients who progressed to a severe disease status, and a stratification analysis was performed. Univariate and multivariate regression analyses were performed to identify influencing factors that may affect the outcome. Further, we used propensity score matching (PSM) to assess the effect of HSYF intervention on the conversion of mild and moderate to a severe disease status. Totally, 721 mild and moderate COVID-19 patients were enrolled, including 430 HSYF users (exposed group) and 291 non-users (control group). No cases in the exposed group and 19 (6.5 %, P < 0.001) cases in the control group progressed to severe disease, and the difference between the two groups (exposed group-control group) was −6.5 % [95 % confidence interval (CI): (−8.87 %, −4.13 %)]. Univariate regression analysis revealed sex (male), age, fever, cough, and fatigue as risk factors for progression to severe disease. After PSM, none of the HSYF users and 7 (4.7 %, P = 0.022) non-users transitioned to severe disease, and the difference between the two groups (exposed group-control group) was −4.7 % [95 % CI: (−8.2 %, −1.2 %)]. Multivariate regression analysis revealed that sex (male) [OR: 3.145; 95 % CI: 1.036–9.545; P = 0.043] and age (> 48 years) [odds ratio (OR): 1.044; 95 % CI: 1.001–1.088; P = 0.044] were independent risk factors for conversion to severe disease. Therefore, HSYF can significantly reduce the progression to severe disease in patients with mild and moderate COVID-19, which may effectively prevent and treat the disease. However, further larger clinical studies are required to verify our results." @default.
• W3048049209 created "2020-08-13" @default.
• W3048049209 creator A5001082066 @default.
• W3048049209 creator A5004987000 @default.
• W3048049209 creator A5009090854 @default.
• W3048049209 creator A5014475708 @default.
• W3048049209 creator A5014841945 @default.
• W3048049209 creator A5036477294 @default.
• W3048049209 creator A5037051241 @default.
• W3048049209 creator A5039504128 @default.
• W3048049209 creator A5044902751 @default.
• W3048049209 creator A5067406811 @default.
• W3048049209 creator A5071798264 @default.
• W3048049209 creator A5073555542 @default.
• W3048049209 creator A5082588749 @default.
• W3048049209 creator A5083914485 @default.
• W3048049209 creator A5084854649 @default.
• W3048049209 date "2020-11-01" @default.
• W3048049209 modified "2023-10-03" @default.
• W3048049209 title "Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study" @default.
• W3048049209 cites W2010231958 @default.
• W3048049209 cites W2131455981 @default.
• W3048049209 cites W2750096820 @default.
• W3048049209 cites W2964412545 @default.
• W3048049209 cites W2999318660 @default.
• W3048049209 cites W3003465021 @default.
• W3048049209 cites W3004517278 @default.
• W3048049209 cites W3007104434 @default.
• W3048049209 cites W3008237982 @default.
• W3048049209 cites W3008421357 @default.
• W3048049209 cites W3012379316 @default.
• W3048049209 cites W3012900537 @default.
• W3048049209 cites W3013552499 @default.
• W3048049209 cites W3140160706 @default.
• W3048049209 cites W4376522314 @default.
• W3048049209 doi "https://doi.org/10.1016/j.phrs.2020.105127" @default.
• W3048049209 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7416080" @default.
• W3048049209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32791263" @default.
• W3048049209 hasPublicationYear "2020" @default.
• W3048049209 type Work @default.
• W3048049209 sameAs 3048049209 @default.
• W3048049209 citedByCount "34" @default.
• W3048049209 countsByYear W30480492092021 @default.
• W3048049209 countsByYear W30480492092022 @default.
• W3048049209 countsByYear W30480492092023 @default.
• W3048049209 crossrefType "journal-article" @default.
• W3048049209 hasAuthorship W3048049209A5001082066 @default.
• W3048049209 hasAuthorship W3048049209A5004987000 @default.
• W3048049209 hasAuthorship W3048049209A5009090854 @default.
• W3048049209 hasAuthorship W3048049209A5014475708 @default.
• W3048049209 hasAuthorship W3048049209A5014841945 @default.
• W3048049209 hasAuthorship W3048049209A5036477294 @default.
• W3048049209 hasAuthorship W3048049209A5037051241 @default.
• W3048049209 hasAuthorship W3048049209A5039504128 @default.
• W3048049209 hasAuthorship W3048049209A5044902751 @default.
• W3048049209 hasAuthorship W3048049209A5067406811 @default.
• W3048049209 hasAuthorship W3048049209A5071798264 @default.
• W3048049209 hasAuthorship W3048049209A5073555542 @default.
• W3048049209 hasAuthorship W3048049209A5082588749 @default.
• W3048049209 hasAuthorship W3048049209A5083914485 @default.
• W3048049209 hasAuthorship W3048049209A5084854649 @default.
• W3048049209 hasBestOaLocation W30480492091 @default.
• W3048049209 hasConcept C126322002 @default.
• W3048049209 hasConcept C144301174 @default.
• W3048049209 hasConcept C167135981 @default.
• W3048049209 hasConcept C17923572 @default.
• W3048049209 hasConcept C201903717 @default.
• W3048049209 hasConcept C2779134260 @default.
• W3048049209 hasConcept C3008058167 @default.
• W3048049209 hasConcept C38180746 @default.
• W3048049209 hasConcept C44249647 @default.
• W3048049209 hasConcept C524204448 @default.
• W3048049209 hasConcept C71924100 @default.
• W3048049209 hasConcept C72563966 @default.
• W3048049209 hasConceptScore W3048049209C126322002 @default.
• W3048049209 hasConceptScore W3048049209C144301174 @default.
• W3048049209 hasConceptScore W3048049209C167135981 @default.
• W3048049209 hasConceptScore W3048049209C17923572 @default.
• W3048049209 hasConceptScore W3048049209C201903717 @default.
• W3048049209 hasConceptScore W3048049209C2779134260 @default.
• W3048049209 hasConceptScore W3048049209C3008058167 @default.
• W3048049209 hasConceptScore W3048049209C38180746 @default.
• W3048049209 hasConceptScore W3048049209C44249647 @default.
• W3048049209 hasConceptScore W3048049209C524204448 @default.
• W3048049209 hasConceptScore W3048049209C71924100 @default.
• W3048049209 hasConceptScore W3048049209C72563966 @default.
• W3048049209 hasLocation W30480492091 @default.
• W3048049209 hasLocation W30480492092 @default.
• W3048049209 hasOpenAccess W3048049209 @default.
• W3048049209 hasPrimaryLocation W30480492091 @default.
• W3048049209 hasRelatedWork W2022044594 @default.
• W3048049209 hasRelatedWork W2050583520 @default.
• W3048049209 hasRelatedWork W2384980663 @default.
• W3048049209 hasRelatedWork W2913104461 @default.
• W3048049209 hasRelatedWork W2999114503 @default.
• W3048049209 hasRelatedWork W4205338151 @default.
• W3048049209 hasRelatedWork W4235834539 @default.
• W3048049209 hasRelatedWork W4282920017 @default.

• next